IDEXX Laboratories, Inc. — Q1 2015 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three months ended March 31, 2015, compared with the three months ended March 31, 2014. IDEXX operates primarily through Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other segments. Effective January 1, 2015, the Company completed its transition to an all-direct U.S. sales model for rapid assay kits and instrument consumables.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $382.5 million | $360.2 million | 6.2% |
| Gross profit | $215.5 million | $202.1 million | 6.7% |
| Gross margin | 56.4% | 56.1% | 30 bps |
| Operating income | $72.8 million | $70.0 million | 3.9% |
| Operating margin | 19.0% | 19.4% | (40) bps |
| Net income attributable to IDEXX | $46.6 million | $46.6 million | Flat |
| Diluted EPS | $0.98 | $0.89 | 10.1% |
| Net cash provided by operating activities | $(14.6) million | $33.5 million | $(48.2) million |
Net margin was approximately 12.2%, compared with 12.9% in the prior-year quarter. Interest expense increased to $6.3 million from $2.8 million, primarily because of additional senior notes and higher average revolving-credit borrowings. The effective tax rate declined to 30.4% from 31.2%.
- CAG revenue was $324.5 million, up 8.6% reported and 13.5% organically.
- Water revenue was $21.7 million, up 1.3% reported and 6.3% organically.
- LPD revenue was $31.3 million, down 8.6% reported but up 2.8% organically.
- Other revenue was $5.0 million, down 14.8% reported and 13.7% organically.
- U.S. revenue increased 13.4%; international revenue declined 3.6% reported but increased 9.2% organically.
Liquidity, cash flow and capital structure
- Cash and cash equivalents were $182.2 million and marketable securities were $139.2 million at March 31, 2015, for total cash, cash equivalents and marketable securities of $321.4 million.
- Working capital was $5.5 million, compared with negative working capital of $61.5 million at December 31, 2014.
- Total debt was approximately $1.05 billion, consisting of $549.5 million outstanding under the revolving credit facility and $500.0 million of long-term debt.
- Remaining borrowing availability under the $700 million credit facility was $149.5 million, before consideration of a $1.0 million letter of credit.
- Operating cash flow was negative because of increased accounts receivable, inventory purchases, accrued-liability payments and working-capital requirements associated with the direct-sales transition.
- Investing cash outflows were $160.6 million, including $140.4 million of marketable-securities purchases and $23.0 million of capital expenditures.
- Financing cash inflows were $36.8 million, including $150.0 million of new long-term debt, partly offset by $133.6 million of share repurchases.
- Management estimated 2015 capital expenditures of approximately $100 million and stated that available liquidity and expected financing capacity should fund operations, capital requirements and anticipated growth needs for the next twelve months.
Material changes versus the prior comparable period
- Reported revenue growth benefited from distributor-margin capture following the U.S. direct-sales transition; management estimated the transition increased reported U.S. revenue growth by approximately 5%.
- CAG recurring revenue increased 9.0% reported and 14.1% organically, led by VetLab consumables and reference-laboratory services.
- CAG operating income declined 2.9% as sales and marketing, general and administrative, and research and development expenses rose faster than revenue.
- Water operating margin improved to 43.6% from 37.9%, partly because royalties expired at December 31, 2014.
- LPD operating income declined 28.5%, reflecting lower reported revenue and an unfavorable comparison with a prior-year royalty benefit.
- Share repurchases increased to $133.6 million from $70.3 million, with 859,009 shares repurchased under the program.
- Weighted-average diluted shares declined to 47.8 million from 52.3 million, supporting the increase in diluted EPS despite essentially flat net income.
- Foreign-currency movements reduced revenue by approximately $21.3 million, operating profit by $5.4 million and diluted EPS by $0.08, net of $4.5 million of operating-profit benefit from hedging gains.
Guidance, outlook, commentary and risks
- At the Company’s then-current exchange-rate assumptions, management expected 2015 currency movements to reduce revenue by approximately $89.1 million, operating profit by $18.4 million and diluted EPS by $0.27, net of anticipated hedging benefits.
- Management expected the direct-sales model to provide continuing distributor-margin capture and operating-profit benefits, but also anticipated higher inventory, accounts receivable, freight, distribution, sales and customer-support requirements.
- The Company identified a 10% strengthening of the U.S. dollar as potentially reducing operating income by approximately $9 million based on projected 2015 revenue and expenses, excluding certain intercompany and monetary-balance effects.
- Key risks include foreign-exchange volatility, increased competition and technological advances, execution of the all-direct U.S. sales model, economic conditions affecting veterinary and other customer spending, market-value fluctuations in the investment portfolio, and ordinary-course litigation.
- The Company held $139.2 million of high-investment-grade marketable securities with maturities of two years or less; a 1% increase in market interest rates was estimated to reduce their fair value by approximately $1.1 million.
- The Company was in compliance with its debt covenants at March 31, 2015. The applicable leverage-ratio covenant was 3.5-to-1.
- No material effect from pending legal proceedings was expected by management, although adverse resolutions could materially affect a particular period.
- Management concluded that disclosure controls were effective and reported no material changes in internal control over financial reporting.
Most important facts for investors to verify
- Whether organic CAG growth and recurring revenue momentum continue after separating distributor-margin capture from underlying practice-level demand.
- The sustainability of operating margins as direct-sales investments, freight and distribution costs, and commercial spending scale.
- Conversion of negative first-quarter operating cash flow into cash generation during the remainder of 2015 and the resulting working-capital needs.
- Leverage, interest expense and covenant headroom following the additional $150 million of senior notes and existing revolving-credit borrowings.
- The actual impact of foreign-exchange movements relative to management’s 2015 assumptions and the effectiveness and duration of hedging.
- Competitive pressure on rapid assay products, particularly earlier-generation feline and canine SNAP products, and the impact of former U.S. distributors carrying competing products.
- The performance, liquidity and credit quality of the newly established marketable-securities portfolio.